摘要
目的 观察司库奇尤单抗联合中药熏洗治疗中重度斑块状银屑病的临床疗效及不良反应。方法 本研究共纳入68例中重度斑块状银屑病患者,使用随机数表法划分成两组,各34例,对照组予以自拟养血润燥祛风汤熏洗及他克莫司软膏治疗;治疗组患者在对照组基础上接受司库奇尤单抗300 mg治疗。两组患者均需持续按疗程完成≥24周的临床观察,并于治疗前及治疗后第4、12、24周时分析银屑病皮损面积及严重程度指数(PASI)、体表受累面积(BSA)、皮肤病生活质量指数(DLQI)的变化来评估临床疗效,并对其药物不良反应进行分析。结果 两组患者均完成了24周临床观察,无患者因药物不耐受或药物不良反应而退出研究。在治疗第4周、12周、24周后,治疗组较对照组PASI评分、BSA评分、DLQI评分前后差值的差异均有统计学意义(P<0.05);除第4周时PASI 100应答率差异无统计学意义外(P=0.063),PASI 75/90/100应答率差异均有统计学意义(P<0.05);DLQI 0/1应答率差异均有统计学意义(P<0.001)。结论 司库奇尤单抗联合中药熏洗治疗中重度斑块状银屑病,可获得较高的PASI 75/90/100及DLQI 0/1应答率,并具有较高的安全性。
Objective To observe the clinical efficacy and adverse reaction of secukinumab with herbal fumigation in the treatment of patients with moderate to severe plaque psoriasis.Methods A total of 68 patients with moderate to severe plaque psoriasis were randomly divided into two groups by digital table method,with 34 cases in each group.The control group was treated with self-made traditional Chinese medicine Yangxue Runzao Qufeng soup and tacrolimus ointment,and the treatment group was received treatment with 300 mg of Sikuximab on the basis of the control group.Both groups will require continuous observation for at least 24 weeks.The efficacy was assessed by the changes of Psoriasis Area and Severity Index(PASI),Body Surface Area(BSA),and Dermatology Life Quality Index(DLQI) before treatment and at weeks 4,12,and 24.The adverse drug reaction was also analyzed.Results After 24 weeks of treatment,no patient exit from the study due to drug intolerance or adverse drug reactions.After weeks 4,12 and 24,there were significant differences in PASI score,BSA score and DLQI score in the treatment group compared with the control group(P <0.05);Except that there were no significant difference in PASI 100response rate at week 4(P=0.063),PASI 75/90/100 response rates were all statistically significant(P<0.05);and DLQI 0/1response rates were also significant differences(P<0.001).Conclusion Secukinumab with herbal fumigation in the treatment of patients with moderate to severe plaque psoriasis can obtain high PASI 75/90/100 and DLQI 0/1 response rates and has a relatively high safety profile.
作者
李玉锋
李树香
刘美娟
LI Yu-feng;LI Shu-xiang;LIU Mei-juan(Dermatology Department,Wudi County Traditional Chinese Medicine Hospital,Binzhou Shandong,251900,China)
出处
《中华养生保健》
2025年第4期9-13,共5页
CHINESE HEALTH CARE
